A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome

Digestive and Liver Disease

Volumn 47, Issue 2, 2015, Pages 119-124

  Pineton de Chambrun, Guillaume ^a,b,c   Neut, Christel ^b,c   Chau, Amélie ^a,b,c   Cazaubiel, Murielle ^d   Pelerin, Fanny ^e   Justen, Peter ^e   Desreumaux, Pierre ^a,b,c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ DE LILLE   (France)

^d Mérieux NutriSciences Company   (France)

^e Lesaffre International   (France)

Author keywords

Abdominal pain; Irritable bowel syndrome; Probiotic; Saccharomyces cerevisiae; Yeast

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLADDER TUMOR; BLOATING; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EVALUATION STUDY; FECES; FEMALE; FLU LIKE SYNDROME; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; HEMORRHOID; HUMAN; IRRITABLE COLON; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SACCHAROMYCES CEREVISIAE; TREATMENT RESPONSE; URINARY TRACT INFECTION; COMPARATIVE STUDY; COMPLICATION; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PROBIOTICS; SACCHAROMYCES CEREVISIAE; TREATMENT OUTCOME;

EID: 84921265988     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.11.007     Document Type: Article

References (29)

1. Camilleri M., Choi M.G. Review article: irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 1997, 11:3-15.
2. Fortea J., Prior M. Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden. Journal of Medical Economics 2013, 16:329-341.
3. Sethi S., Wadhwa V., LeClair J., et al. In-patient discharge rates for the irritable bowel syndrome - an analysis of national trends in the United States from 1997 to 2010. Alimentary Pharmacology and Therapeutics 2013, 38:1338-1346.
4. Irvine E.J., Whitehead W.E., Chey W.D., et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006, 130:1538-1551.
5. Bellini M., Gambaccini D., Stasi C., et al. Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World Journal of Gastroenterology 2014, 20:8807-8820.
6. Lee K.N., Lee O.Y. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World Journal of Gastroenterology 2014, 20:8886-8897.
7. Jeffery I.B., Quigley E.M., Ohman L., et al. The microbiota link to irritable bowel syndrome: an emerging story. Gut Microbes 2012, 3:572-576.
8. Spiller R., Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009, 136:1979-1988.
9. Collins S.M. A role for the gut microbiota in IBS. Nature Reviews Gastroenterology & Hepatology 2014, 11:497-505.
10. Guarner F., Requena T., Marcos A. Consensus statements from the Workshop "Probiotics and Health: Scientific Evidence". Nutrición Hospitalaria 2010, 25:700-704.
11. Moayyedi P., Ford A.C., Talley N.J., et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010, 59:325-332.
12. Rousseaux C., Thuru X., Gelot A., et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nature Medicine 2007, 13:35-37.
13. Rousseaux C., Bouguen G., Dubuquoy C., et al. Saccharomyces cerevisiae CNCM I-3856 decreases intestinal pain through PPAR alpha activation in the gut. Gastroenterology 2010, 138:S51.
14. Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
15. Kurtzman C.P., Robnett C.J. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5' end of the large-subunit (26S) ribosomal DNA gene. Journal of Clinical Microbiology 1997, 35:1216-1223.
16. Kurtzman C.P., Robnett C.J. Identification and phylogeny of ascomycetous yeasts from analysis of nuclear large subunit (26S) ribosomal DNA partial sequences. Antonie Van Leeuwenhoek 1998, 73:331-371.
17. European Committee for Standardization, Animal feeding stuffs PCR typing of probiotic strains of Saccharomyces cerevisiae (yeast) 2009, CEN/TS 15790:2008. 16 pages.
18. Andresen V., Montori V.M., Keller J., et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clinical Gastroenterology and Hepatology 2008, 6:545-555.
19. Corazziari E., Bytzer P., Delvaux M., et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2003, 18:569-580.
20. O'Donnell L.J., Virjee J., Heaton K.W. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. British Medical Journal 1990, 300:439-440.
21. Ford A.C., Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2010, 32:144-158.
22. Spiller R.C. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. American Journal of Medicine 1999, 107:91S-97S.
23. Patel S.M., Stason W.B., Legedza A., et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterology and Motility 2005, 17:332-340.
24. Bardhan K.D., Bodemar G., Geldof H., et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2000, 14:23-34.
25. Tack J., Müller-Lissner S., Bytzer P., et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005, 54:1707-1713.
26. Romanin D., Serradell M., González Maciel D., et al. Down-regulation of intestinal epithelial innate response by probiotic yeasts isolated from kefir. International Journal of Food Microbiology 2010, 140:102-108.
27. Choi C.H., Jo S.Y., Park H.J., et al. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. Journal of Clinical Gastroenterology 2011, 45:679-683.
28. Kabir M.A., Ishaque S.M., Ali M.S., et al. Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome. Mymensingh Medical Journal 2011, 20:397-401.
29. Lee S.K., Kim H.J., Chi S.G., et al. Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cell. Korean Journal of Gastroenterology 2005, 45:328-334.